(NCDR PINNACLE) observed that 43.9% of cholesterol treatmenteligible primary-prevention patients were receiving a statin medication and up to 35.9% were not receiving any lipid-lowering therapy. 3 Downstream costs associated with the care of patients presenting with ASCVD events are tremendous. However, more robust implementation of primary-prevention therapies is complicated by the fact that the United States is in the midst of a shortage of primary-care physicians and cardiologists. 4 Advanced practice providers (APPs) may provide an opportunity to fill this vital gap in the healthcare delivery team to both expand access and relieve some burden from primary-care managers. [5] [6] [7] The appropriate utilization of APPs in a primary-prevention, subspecialty clinic population has the possibility to positively impact adherence to guideline-directed therapy, as it has been shown to do in secondary-prevention, diabetes mellitus (DM), and heart failure populations previously. 4, 8, 9 We sought to analyze the effectiveness of risk stratification, initiation of recommended medical therapies, and resultant changes in global ASCVD risk by APPs with indirect oversight by a cardiologist utilizing locally developed treatment algorithms based on published guidelines.
| METHODS

| Study population
A population of 595 patients without known ASCVD referred to a preventive cardiology clinic (PCC) at a single-center military treatment facility from January 1, 2009, to December 31, 2013 , was included in the study population. Baseline demographic data, initial and follow-up laboratory and imaging data, and cardiovascular risk factors were
abstracted. An age and risk-factor propensity-matched cohort (PMC) was derived in a 1:1 fashion from an initial population of 20 604 patients enrolled in internal medicine and family medicine clinics in the same healthcare system over the same time period.
| The PCC
The PCC is embedded within the cardiology division and utilizes a clinical pharmacist, physician assistants, and a nurse practitioner supervised by a board-certified cardiologist. The PCC accepts primary-prevention adult patients from primary-care clinics and other specialty-care clinics within the local healthcare system. The APPs manage primaryprevention medications and pursue smoking cessation working with a guideline-based, locally developed algorithm utilizing Framingham Risk Score (FRS) and coronary artery calcium scoring (CACS). Treatment and follow-up testing decisions are made by APPs independently. 
| Initial evaluation
| CACS
The CACS studies were obtained using an electrocardiogram gated 
| Management of DM
Patients with initial HbA1c levels >7.0% were considered for initiation of antihyperglycemic therapies. Recommended annual screening for microalbuminuria, peripheral neuropathy, and diabetic retinopathy was also performed. Patients achieving target HbA1c levels were monitored in 3-to 6-month intervals, whereas patients with persistently elevated HbA1c levels were referred to a specialized DM care
clinic within the endocrinology division for evaluation of insulin or other more advanced therapies.
| Tobacco-cessation counseling
All patients referred to the PCC were screened for tobacco use.
Patients willing to quit were referred to a weekly tobacco-cessation information class, as well as assessed for individualized intervention intensity level. Interventions ranged from a single counseling session without pharmacotherapy intervention to ≥6 counseling sessions, pharmacotherapeutic initiation, short-interval clinic follow-up, and referral to a weekly support group.
| Follow-up
Follow-up FRS in all patients was performed based on data obtained 12 months (AE6 months) from the initial clinic encounter. Changes in BP and lipids were calculated as percent changes from baseline laboratory and BP data, with a positive percentage representing a favorable change and a negative percentage indicating a negative change.
Initial and follow-up laboratory data within 6 months prior to the initial primary-care visit were labeled as baseline data, and follow-up laboratory data ≥3 months after the initial visit was abstracted and used to assess follow-up therapy and laboratory changes. 3 | RESULTS
| Statistical analysis
| Clinical characteristics
The baseline clinical characteristics for the PCC and PMC patient groups are shown in Table 1 . The PCC group was more likely to be treated initially for HTN (P < 0.001). Otherwise, baseline demographics and cardiac risk factors were well balanced between the groups. The median FRS at initial evaluation was higher in the PCC cohort (15.9%) compared with the PMC patients (11.5%; P < 0.001).
This was driven by more high-FRS patients (P < 0.001) and fewer low-FRS patients (P < 0.001) in the PCC cohort (Table 1) . 
| CACS
| Lipid management
Patients in the PCC had lower baseline LDL-C (P = 0.036) and were more commonly on a high-intensity statin (P = 0.013) and nonstatin Post-intervention, median LDL-C values were reduced in the PCC cohort compared with PMC patients (P < 0.001; Figure 1A ). More high-FRS PCC patients (Table 2 ) achieved an LDL-C < 70 mg/dL (P = 0.005) and a non-high-density lipoprotein cholesterol (non-HDL-C) of <130 mg/dL (P < 0.001). Additionally, reduction in median LDL-C (P = 0.030), non-HDL-C (P = 0.001), and triglycerides (P = 0.009) was observed in the PCC cohort (Table 2) .
CACS-stratified changes in median LDL-C ( Figure 2B ) were also significant in that patients with a CACS >100 AU had a more dramatic reduction in LDL-C post-intervention than did those with CACS of <100 AU (P < 0.001). The algorithm-driven risk-factor management among PCC patients resulted in significant reductions in median FRS across all risk categories when compared with PMC patients (P < 0.001 for all groups; Figure 2C ).
| Management of BP
Baseline BP readings (Table 1) were well controlled (defined as SBP ≤120 mm Hg) in more than three-quarters of the patients in both groups (P = 1.000). There was no difference in mean SBP between the 2 cohorts post-intervention (126 AE13 mm Hg vs 129 AE14 mm Hg; P = 0.189) or the rate of well-controlled SBP (P = 0.134). There was a substantial 4% to 5% reduction in SBP in the high-FRS patients (Table 2) (Table 2) .
| DISCUSSION
The use of APPs in a PCC utilizing guideline-based local risk factormodification algorithms, combined with routine utilization of CACS, resulted in higher rates of lipid-lowering therapy initiation in treatment-naïve patients, more frequent appropriate escalation of lipid-lowering therapy, and more frequent use of combination lipid- health systems within a primary-care setting. 19 The PCC model presented in this analysis differs from published data in several ways.
Through the creation of algorithms of care, there was less ambiguity for APPs regarding escalation of medical care. Additionally, the breadth of ASCVD risk factors addressed within a single clinic is novel.
Finally, the frequent, up-front utilization of CACS to individualize ASCVD risk stratification allowed for a more patient-centered approach to primary prevention and may have improved compliance with recommended therapies.
ASCVD events continue to be the primary cause of morbidity and mortality in the first world. Data suggest that both physicians and APPs practicing within cardiology clinics do not routinely prescribe recommended medical therapies for various ASCVD events in patients who meet guideline criteria to be offered therapy. Physicians and APPs were compliant with ASCVD medication interventions in approximately 12% of patients in a large PINNACLE NCDR registry. 4 In our analysis, treatment in a PCC cohort resulted in 85.8% of patients eligible for lipid-lowering therapy actually being on lipidlowering therapy, which is tremendously higher than reported compliance rates. More striking is the fact that compliance with lipid therapies was high at baseline in both cohorts (approximately 50%), thus demonstrating that this model is effective even in high-compliance healthcare systems.
Costs associated with care in our 2 cohorts could not be calculated due to a lack of patient-level billing data; however, the potential cost implications of improved ASCVD event prevention, in addition to direct patient care administered by APPs, has been demonstrated. 20 Medicare reimburses for care administered by APPs at up to 85% of a physician's rate. 21 Costs associated with long-term management of patients following a ASCVD event are higher, as shown in DM populations, among others. 22 Thus, higher rates of medication compliance observed in our PCC cohort would be assumed to lead to lower downstream event rates and reduction in direct costs due to APPs delivering the care and fewer hospitalizations/revascularization procedures.
Additionally, indirect costs may decrease as a result of increased patient productivity, decreased days off work, and increased qualityadjusted life-years.
Utilization of CACS as part of the initial risk-stratification strategy was very high within the PCC cohort, at nearly 83%. trial showed that use of CACS resulted in a lower FRS at 4 years of follow-up when compared with no scanning. 28 Additionally, a CACSbased strategy was also associated with favorable changes in SBP (P = 0.02), LDL-C (P = 0.04), and waist circumference (P = 0.01), without increased downstream medical testing. 28 A recently published meta-analysis found that, compared with risk-assessment strategies not involving CACS, individuals found to have CAC were more likely to be started on aspirin, statin therapy, and antihypertensive medications or to have intensification of baseline medical therapy. 
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